FYI: Genentech has a very prominent floating advertisement for advanced BCC treatment in the physician section of WebMD. If you open the web site for continuing ed or for other purposes a large floating window drops down that leads to 4 pages of info very similar to the NEJM article. It includes new dramatic pics of advanced bcc that I had not seen before.
I think it is safe to assume that they would be paying for this advertisement space unless they were pretty certain of quick approval for Vismodegib.
i'm hopeful/confident of approval, but ... counting chickens before they hatch in biotech can be dangerous. i've seen biotechs hire and train salespersons in anticipation of the "sure thing" that never happened.
Ace, it is great how total strangers come together on this message board to help others with their due diligence and I also appreciate those who continue to provide valuable information.
I can't imagine the FDA not approving this but they have done weird things in the past. I will be very surprised if we have to wait past the end of January for approval and personally I think we could find out any day. The FDA isn't requiring any panel to be convened which to me speaks volumes about our prospects for approval. Couple that with the fact that there are no other treatment options for this indication along with a very good safety profile and how could they delay the approval? Now we just need positive word out of the EU about our application status there and operable bcc results any day and things can get really exciting for Curis longs.